Overview

GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA)

Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
An investigator-initiated double-blind, parallel-group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes.
Phase:
Phase 3
Details
Lead Sponsor:
The Leeds Teaching Hospitals NHS Trust
Collaborator:
Janssen Pharmaceutica N.V., Belgium
Treatments:
Antibodies, Monoclonal
Golimumab
Methotrexate